Adocia to Host Virtual KOL Event Reviewing Phase 3 Results of Ultra-Rapid Insulin BioChaperone Lispro in Type 2 Diabetes
核心洞察
Adocia will host a virtual Key Opinion Leader event on June 16, 2026, to present Phase 3 clinical trial results for BioChaperone Lispro (搜索) in type 2 diabetes (搜索).
Dr. Tim Heise, co-founder of Profil Research Institute (搜索), will present the data alongside Adocia's CEO Olivier Soula and Head of R&D You-Ping Chan.
BioChaperone Lispro (搜索) is an ultra-rapid prandial insulin combining Adocia's BioChaperone technology with insulin lispro, designed to reduce post-meal hyperglycemia and minimize hypoglycemia risk.
Adocia, a clinical-stage biopharmaceutical company focused on metabolic diseases, announced it will host a virtual Key Opinion Leader (KOL) event on Tuesday, June 16, 2026, at 10:00 a.m. EST / 4:00 p.m. CEST to review Phase 3 clinical trial results for its ultra-rapid insulin candidate, BioChaperone Lispro (搜索) (BC Lispro), in the treatment of type 2 diabetes (搜索).
The event, titled "Advancing Mealtime Insulin Therapy: Phase 3 Results for BC Lispro in Type 2 Diabetes (搜索)," will feature Dr. Tim Heise, Lead Scientist, Chairman of the Board of Directors, and co-founder of the Profil Research Institute (搜索) in Neuss, Germany. Dr. Heise will be joined by Adocia's CEO and co-founder Olivier Soula and Head of R&D You-Ping Chan.
Event Agenda and Presenters
The virtual event will cover four key topics: an introduction to Adocia's proprietary BioChaperone technology platform by You-Ping Chan; a review of the current mealtime insulin treatment paradigm and its limitations by Dr. Tim Heise; presentation of the Phase 3 data for BC Lispro in type 2 diabetes (搜索), also by Dr. Heise; and a discussion of next steps and potential value creation led by Olivier Soula. A live question and answer session will follow the presentations. The webcast will be conducted in English, with a replay and presentation materials made available on Adocia's website following the event.
Dr. Heise brings extensive expertise to the event, having led numerous studies on the pharmacology of novel anti-diabetic agents and insulins. He has published more than 250 scientific papers and reviews and serves on the editorial boards of Diabetes, Obesity and Metabolism and Diabetes Technology & Therapeutics.
BioChaperone Lispro (搜索): An Ultra-Rapid Insulin
BioChaperone Lispro (搜索) belongs to the latest generation of prandial insulins, combining Adocia's proprietary BioChaperone technology with insulin lispro, the active ingredient in the standard-of-care therapy Humalog (Eli Lilly). The formulation is designed to act significantly faster than earlier insulin generations, effectively reducing post-meal hyperglycemia — a key contributor to long-term complications such as retinopathy, diabetic foot ulcers, and kidney failure.
The rapid elimination profile of BioChaperone Lispro (搜索) also minimizes the risk of hypoglycemia, which can occur when insulin levels remain elevated after post-meal glucose levels have normalized. According to Adocia, the faster action profile, combined with excellent local tolerance, enhances compatibility with modern diabetes management systems, particularly insulin pump systems, and enables better integration into advanced treatment algorithms.
Beyond clinical advantages, the quick onset of BioChaperone Lispro (搜索) offers greater flexibility in dose timing. Patients can administer insulin at mealtime or even right after a meal, allowing for more accurate dosing based on known meal timing and content. This flexibility reduces the risks of overdosing or underdosing, which can lead to hypo- or hyperglycemia and their associated complications. The simplified dosing process is also expected to ease the psychological burden on patients and caregivers, alleviating the stress associated with diabetes management.
Strategic Partnership and Development Pathway
BioChaperone Lispro (搜索) was licensed to Tonghua Dongbao (搜索) in 2018 as part of a licensing agreement covering China and other Asian countries. The Phase 3 trial whose results will be presented was conducted in China.
Adocia, headquartered in Lyon, France, employs approximately 80 people and holds more than 25 patent families. The company specializes in therapeutic solutions for metabolic diseases, primarily diabetes and obesity, and maintains a portfolio built on four proprietary technology platforms: BioChaperone for peptide stabilization and enhancement, AdOral for oral peptide delivery, AdoShell for immunoprotective biomaterials in cell transplantation, and AdoXLong for long-acting peptide formulations. Adocia is listed on the Euronext Paris regulated market (Euronext: ADOC; ISIN: FR0011184241).